Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across multiple tumor types...
Optimal therapeutic targeting of cancer involves clonal signals which are expressed within all cancer cellsGradalis applies a novel clinically relevant...
NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology...
Distinguished Biotech, Pharmaceutical and Healthcare Leaders Will Headline Three Days of Inspiring Innovation at the 24th Annual Conference & Expo,...
SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the...
Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune® platform...
Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of...
Encouraging Safety Profile Supports Progression Toward First Dual-Administration of Selective A2A and A2B Antagonists in PatientsDOVER, Del., March 12, 2025...
GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a leading public health...
Late-breaking clinical and first translational data from BOND-003 Cohort C will be presentedIRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) --...
Trial for this rare genetic disease to be conducted by NIH/NIAID in partnership with Corvus ITK inhibition intended to address...
Dr. Anatoly Dritschilo remains Chairman of the Board and Co-CEO overseeing scientific and clinical trial activitiesGAITHERSBURG, Md., March 12, 2025...
On-demand video webcast now available Includes latest updates on pancreatic cancer and bird flu clinical trials OCALA, Fla., March 11,...
• COEP forms GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for...
PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage...
– Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with...
Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research SessionMarlborough, Massachusetts--(Newsfile Corp. - March 10, 2025) -...
MILAN and TEL HASHOMER, Israel, March 10, 2025 /PRNewswire/ -- Tethis S.p.A., a pioneer in standardized liquid biopsy platform development, and...
First-ever HPV16-positive head and neck cancer Phase 3 clinical trialPRINCETON, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation...
Leveraging Advanced AI and Robotics to Revolutionize Marketing Strategies in Defense and Security SectorsWEXFORD, Pa., March 07, 2025 (GLOBE NEWSWIRE)...